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Disrupted sphingolipid metabolism following acute clozapine and
olanzapine administration
Abstract

Background: Second generation antipsychotics (SGAs) induce glucometabolic side-effects, such as
hyperglycemia and insulin resistance, which pose a therapeutic challenge for mental illness. Sphingolipids play
a role in glycaemic balance and insulin resistance. Endoplasmic reticulum (ER) stress contributes to impaired
insulin signalling and whole-body glucose intolerance. Diabetogenic SGA effects on ER stress and
sphingolipids, such as ceramide and sphingomyelin, in peripheral metabolic tissues are unknown. This study
aimed to investigate the acute effects of clozapine and olanzapine on ceramide and sphingomyelin levels, and
protein expression of key enzymes involved in lipid and glucose metabolism, in the liver and skeletal muscle.
Methods: Female rats were administered olanzapine (1 mg/kg), clozapine (12 mg/kg), or vehicle (control)
and euthanized 1-h later. Ceramide and sphingomyelin levels were examined using electrospray ionization
(ESI) mass spectrometry. Expression of lipid enzymes (ceramide synthase 2 (CerS2), elongation of very longchain fatty acid 1 (ELOVL1), fatty acid synthase (FAS) and acetyl CoA carboxylase 1 (ACC1)), ER stress
markers (inositol-requiring enzyme 1 (IRE1) and eukaryotic initiation factor (eIF2α) were also examined.
Results: Clozapine caused robust reductions in hepatic ceramide and sphingolipid levels (p < 0.0001),
upregulated CerS2 (p < 0.05) and ELOVL1 (+ 37%) and induced significant hyperglycemia (vs controls). In
contrast, olanzapine increased hepatic sphingomyelin levels (p < 0.05 vs controls). SGAs did not alter
sphingolipid levels in the muscle. Clozapine increased (+ 52.5%) hepatic eIF2α phosphorylation,
demonstrating evidence of activation of the PERK/eIF2α ER stress axis. Hepatic IRE1, FAS and ACC1 were
unaltered. Conclusions: This study provides the first evidence that diabetogenic SGAs disrupt hepatic
sphingolipid homeostasis within 1-h of administration. Sphingolipids may be key candidates in the
mechanisms underlying the diabetes side-effects of SGAs; however, further research is required.
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Disrupted sphingolipid metabolism
following acute clozapine and olanzapine
administration
Katrina Weston-Green1,2* , Ilijana Babic1,2,3, Michael de Santis1,2, Bo Pan4, Magdalene K. Montgomery5,
Todd Mitchell1,2,6, Xu-Feng Huang1,2 and Jessica Nealon2,6

Abstract
Background: Second generation antipsychotics (SGAs) induce glucometabolic side-effects, such as hyperglycemia
and insulin resistance, which pose a therapeutic challenge for mental illness. Sphingolipids play a role in glycaemic
balance and insulin resistance. Endoplasmic reticulum (ER) stress contributes to impaired insulin signalling and
whole-body glucose intolerance. Diabetogenic SGA effects on ER stress and sphingolipids, such as ceramide and
sphingomyelin, in peripheral metabolic tissues are unknown. This study aimed to investigate the acute effects of
clozapine and olanzapine on ceramide and sphingomyelin levels, and protein expression of key enzymes involved
in lipid and glucose metabolism, in the liver and skeletal muscle.
Methods: Female rats were administered olanzapine (1 mg/kg), clozapine (12 mg/kg), or vehicle (control) and
euthanized 1-h later. Ceramide and sphingomyelin levels were examined using electrospray ionization (ESI) mass
spectrometry. Expression of lipid enzymes (ceramide synthase 2 (CerS2), elongation of very long-chain fatty acid 1
(ELOVL1), fatty acid synthase (FAS) and acetyl CoA carboxylase 1 (ACC1)), ER stress markers (inositol-requiring
enzyme 1 (IRE1) and eukaryotic initiation factor (eIF2α) were also examined.
Results: Clozapine caused robust reductions in hepatic ceramide and sphingolipid levels (p < 0.0001), upregulated
CerS2 (p < 0.05) and ELOVL1 (+ 37%) and induced significant hyperglycemia (vs controls). In contrast, olanzapine
increased hepatic sphingomyelin levels (p < 0.05 vs controls). SGAs did not alter sphingolipid levels in the muscle.
Clozapine increased (+ 52.5%) hepatic eIF2α phosphorylation, demonstrating evidence of activation of the PERK/
eIF2α ER stress axis. Hepatic IRE1, FAS and ACC1 were unaltered.
Conclusions: This study provides the first evidence that diabetogenic SGAs disrupt hepatic sphingolipid
homeostasis within 1-h of administration. Sphingolipids may be key candidates in the mechanisms underlying the
diabetes side-effects of SGAs; however, further research is required.
Keywords: Antipsychotic, Sphingolipid, Ceramide, Sphingomyelin, ER stress, Hyperglycemia

Background
Second generation antipsychotics (SGAs), such as olanzapine and clozapine, are approved to treat schizophrenia
and bipolar disorder. SGAs are also increasingly prescribed for a growing number of illnesses in adults and
children [1]. Unfortunately, olanzapine and clozapine can
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cause serious metabolic side-effects, including weight gain,
obesity, and prolonged hyperglycemia that can lead to insulin resistance and diabetes mellitus (DM) [2]. Glucometabolic side-effects can occur independently of weight
gain, suggesting that SGAs could disrupt glucose metabolism directly. Despite almost two decades of scientific research [3], the precise mechanisms underlying the
hyperglycaemic side-effects of these drugs remain unclear.
In addition, reports suggest a recent drying of the antipsychotic drug development pipeline [4]. Therefore, the
hyperglycemia side-effects of SGAs continue to pose a
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critical therapeutic challenge for mental illness and further
mechanistic research is required.
Peripheral tissues, such as the liver, skeletal muscle and
adipose tissues, play important roles in metabolic homeostasis and a growing body of literature demonstrates that
SGAs target these tissues to induce metabolic side-effects
[5–7]. Clinical and experimental studies have shown that
inappropriate hepatic glucose production and peripheral
insulin resistance are major contributors to olanzapineand clozapine-induced prolonged hyperglycemia. For
example, evidence demonstrates that olanzapine and clozapine induce an imbalance in glucagon and insulin [8–10],
favoring hepatic gluconeogenesis, glycogenolysis and suppression of glycogen synthesis. Other studies show that
clozapine induces insulin resistance by directly impairing
insulin receptor (IR) activity and downstream signalling
events (ie reduced IR substrate-1 (IRS-1) phosphorylation)
in mouse skeletal muscle [11], while olanzapine was shown
to upregulate mRNA expression of key gluconeogenic enzymes, leading to hyperglycemia and insulin resistance in
rats [12]. Olanzapine and clozapine also induce the development of hepatic steatosis, with reports of a reduction in
hepatic lipolytic capacity (such as reduced hormonesensitive lipase (HSL)), reduced fatty acid oxidation, as well
as increases in lipogenesis (increased gene expression of
fatty acid synthase (FAS) and acetyl-CoA carboxylase
(ACC), with lipogenic gene expression commonly driven
by a SGA-induced upregulation of sterol regulatory
element-binding protein (SREBP)) [5, 13]. In addition, hepatic lipogenesis and subsequent lipid accumulation can
also be driven by activation of endoplasmic reticulum (ER)
stress, thereby also contributing to glucometabolic imbalance and leading to reduced insulin signalling and wholebody glucose intolerance [7, 14, 15]. ER stress activates
unfolded protein response (UPR) pathways, which act to
reduce the demand for protein folding in an effort to reduce
cellular stress and avert cell apoptosis [16]. Stress in the
ER lumen activates three transmembrane proteins:
inositol-requiring enzyme 1 (IRE1), protein kinase RNAlike endoplasmic reticulum kinase (PERK) and activating
transcription factor 6 (ATF6) that signal to monitor ER
stress. PERK transiently inhibits eukaryotic initiation factor
(EIF-2α) through phosphorylation, while IRE1 triggers
other cell fate signalling pathways, such as c-Jun Nterminal kinase (JNK) that is also a central mediator of insulin signalling and implicated in insulin resistance [7, 14].
In addition, a major downstream intermediate of the IRE1
pathway, X-box binding protein 1, upregulates hepatic
lipogenesis by acting as a transcription factor for lipogenic
genes [17]. However, the effect of diabetogenic SGAs on
these enzymes is unknown.
Sphingolipids also play an important role in glycaemic balance and insulin resistance (see reviews by [18, 19]). Ceramides are a sphingolipid sub-class that contain a fatty acyl
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chain attached to a sphingosine backbone via an amide linkage [20, 21]. Ceramide is synthesised through several metabolic pathways, including the de novo pathway that
produces ceramide in the ER and the salvage pathway where
degradation of complex sphingolipids eventually produces
ceramide. Ceramide synthesis via the de novo pathway involves ceramide synthase enzymes (CerS1–6) that produce
different ceramide species based on their fatty acyl chain
length [22]. The CerS2 isoform yields carbon (C) 22–24
ceramide species and C24 ceramides are reportedly one of
the most abundant species in the body [22–24]. CerS2 also
regulates the elongase enzyme, elongation of very longchain fatty acid 1 (ELOVL1), which synthesises C18-C26
fatty acid chains using C16 as a substrate [25]. Ceramide
production can be inhibited by fatty acid synthase (FAS), a
key enzyme in the synthesis of the lipid precursor palmitate
[4]. Following production in the ER, ceramide can be converted into sphingomyelin in the Golgi [22]. Ceramide and
sphingomyelin are essential structural components of the
plasma cell membrane and are bioactive players in numerous cell processes, including apoptosis and regulation of
protein phosphorylation by ceramide in-vitro [22]. Complex
sphingolipids are required for ER homeostasis and a reduction in sphingolipid levels has been shown to initiate cell
death via ER stress-mediated pathways [26]. Ceramide
inhibits glycogen synthesis and insulin-stimulated glucose
uptake, blockade of ceramide synthesis improves insulin
sensitivity and glucose homeostasis, and levels of ceramide
species are higher in skeletal muscle of obese insulinresistant subjects compared to lean controls [27]. Interestingly, sphingolipids are also altered in schizophrenia, for
example increased ceramide levels have been reported in
the white matter of the pre-frontal cortex [28] (also see
review by Castillo et al. [29]), and in response to chronic
haloperidol treatment, a first generation antipsychotic drug
[30]. Altered sphingolipids in key glucometabolic tissues,
such as the liver and skeletal muscle, may contribute to the
disruption in glucose homeostasis that leads to hyperglycemia and insulin-resistance side-effects; however, this has
not previously been examined. The aim of this study was to
investigate the acute effects of olanzapine and clozapine administration on the levels of ceramide and sphingomyelin in
the liver and skeletal muscle, as well as protein expression
of key enzymes involved in lipid and glucose metabolism.

Methods
Ethics

This study was approved by the Animal Ethics Committee
of the University of Wollongong (AE13/19). Procedures
complied with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes [31].
Efforts were made to minimise animal number and reduce
suffering throughout the experimental process.
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Animals and treatment

Adult female Sprague Dawley rats (~ 200-225 g, 9 weeks)
were obtained from the Animal Resource Centre (Perth,
WA, Australia) and pair-housed at 22 °C (12 h darklight cycle, photophase 07.00 h) with ad libitum access
to water and standard laboratory chow (3.9 kcal/g; fat
10%, carbohydrates 74% and protein 16%) throughout
the study. Female rats were selected based on the increased sensitivity of women to antipsychotic-induced
metabolic side-effects in the clinical scenario [32], a
phenomenon also apparent in female rats [33]. Rats were
habituated for one-week to facilitate environmental acclimatisation. Following an overnight fast (13 ± 2 h), rats
were administered an acute dose of olanzapine (Zyprexa,
Lilly, Indianapolis, USA) (1 mg/kg), clozapine (Clozaril,
Novatis, Basel, Switzerland) (12 mg/kg), or vehicle
(control) (n = 12/group), as we have previously reported
[34–39], then euthanized one-hour post-treatment via
CO2 asphyxiation. Dosages were selected based on human clinical doses, translated to animal equivalent doses
by considering differences in body surface area between
species [40], and our previous reports [34–39]. The 1-h
time period was used in order to determine the immediate
(acute) drug effects on the parameters examined. Blood
samples were immediately obtained and centrifuged
(1000 g, 4 °C, 10 mins), then plasma was analysed in
duplicate for glucose concentrations using commercial
colorimetric glucose oxidase assay kits (Cayman Chemical,
MI, USA). Post-mortem liver and skeletal muscle (gastrocnemius) tissues were dissected and frozen in liquid nitrogen, then stored at − 80 °C for analysis.
Sphingolipid extraction and analysis by mass
spectrometry

The lipid extraction and mass spectrometry methods were
based on a previous study from our laboratory [41]. Briefly,
lipids were extracted using a biphasic methyl-tert-butyl
ether (MTBE) / methanol (HPLC grade, Thermo Scientific,
Scoresby, VIC Australia) lipid extraction technique,
whereby 5 mg of tissue was homogenised (n = 6–7 / group)
in 300 μL methanol and butylated hydroxytoluene (MeOH
+ 0.01% BHT) containing internal standards (SM (d18:0/
12:0) 25 μM and Cer (d18:1/17:0) 5 μM, Avanti Polar
Lipids, AL, USA; 10 μL/mg tissue) for quantification, using
a ceramic bead homogeniser (Fast Prep-24, MP Biomedical, NSW, Australia; 6 m/s for 40 s). Residual tissue was
removed from the beads using an additional 100 μL
MeOH+ 0.01% BHT, then 920 μl of MTBE was added to
the homogenate. Tubes were rotated for one hour at 4 °C,
then 230 μL of 150 mM ammonium acetate (NH4OAc)
was added and samples were briefly vortexed then centrifuged (2000 g, 5 min). The upper organic phase containing
the lipids was collected into a glass vial without disturbing
the lower aqueous phase. The extracted samples
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underwent further base hydrolysis to remove highly abundant phospholipids and allow detection of less abundant
ceramide and sphingomyelin species. A 200 μL aliquot of
extracted sample was combined with MeOH+ 0.01% BHT
and 0.7 M sodium hydroxide. Samples were rotated (2 h,
room temperature) then re-extracted using the same
MTBE and NH4OAc methods above. Samples were vortexed then centrifuged (2000 g, 5 min). The upper organic
phase containing the extracted lipid molecules of interest
was removed and diluted 50-fold in MeOH and chloroform (CHCl3) (2:1 vol/vol) with 5 mM NH4OAc. Diluted
extract (30 μL) was pipetted into a 96-well plate and heatsealed with foil to prevent evaporation of the solvent. The
lipid extracts were analysed by electrospray ionization
(ESI) mass spectrometry using a hybrid triple quadrupole
ion trap mass spectrometer (QTRAP® 5500 AB SCIEX,
Framingham Massachusetts, USA) equipped with an automated chip-based nano-electrpospray source (Triversa
Nanomate®, Advion, Ithaca, NY, USA), as previously
described [41, 42]. Lipid extracts were analysed using precursor ion scans in positive ion mode ([M + H]+) using a
mass to charge ratio (m/z) of 264.4 with a collision energy
of 35 for ceramide, and a m/z of 184.1 and collision energy
of 40 for sphingomyelin, respectively. Further ESI settings
specific to the QTRAP® 5500 were used as previously
reported [41]. Sphingolipid species were quantified against
the internal standards using AB SCIEX Lipidview™
Software (Framingham, Massachusetts, USA) with the
following processing settings, a mass tolerance of 0.5 Da, a
minimum intensity of 0.1% and a minimum signal-tonoise ratio of 25, as we have previously described [41, 43].
Western blot

Levels of protein expression in the tissue samples (n = 4–6 /
group) were examined using standard western blot techniques, as previously described [44, 45]. Briefly, whole tissue
samples were homogenized (Precellys, Sapphire Bioscience
Australia) at 6 m/sec for 30 s in RIPA buffer (65 mmol/l
Tris, 150 mmol/l NaCl, 5 mmol/l EDTA, pH 7.4, 1% (v/v)
NP-40 detergent, 0.5% (w/v) sodium deoxycholate, 0.1% (w/
v) SDS, 10% (v/v) glycerol, containing 25 μg/ml leupeptin,
10 μg/ml aprotinin, 2 mmol/l sodium orthovanadate, 10
mmol/l NaF and 1 mmol/l polymethylsulphonyl fluoride)
[44]. Proteins were resolved using SDS-PAGE techniques
and immunoblotting was performed using the following
antibodies: total ACC (cat 3662), phosphorylated ACC (cat
3661), total Elf2a (cat 9722) and phosphorylated Elf2a (cat
3398) FAS (cat 3180) and total IRE1 (cat 3294) (Cell
Signaling Technology, MA, USA), phosphorylated IRE1
(cat ab48187) (Abcam, Melbourne, Australia), while CerS2
(cat ARP32609) and Elovl1 (cat ARP49759) antibodies were
purchased from Aviva Systems Biology (San Diego, CA,
USA) Bands of interest were quantified by densitometry
using ImageJ 1.44p software (NIH, USA).
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Glycogen content

Liver glycogen content was assayed using a phenolsulphuric acid calorimetric method previously described
[46]. Briefly, 50 mg of liver was digested in 200 μL of
1 M KOH at 70 °C, followed by addition of 75 μL of saturated Na2SO4 and 1.725 mL of 95% ethanol to precipitate
glycogen. Samples were centrifuged at 13000 rpm for
10 min at 4 °C, and the glycogen pellet resuspended in
200 μL of H2O. Once resuspended, 1.8 mL of 95% ethanol
was added, and the samples centrifuged again. The
glycogen pellet was air dried, resuspended in 500 μL of a
solution containing 0.3 mg/mL amyloglucosidase (SigmaAldrich, Castle Hill, NSW Australia) in 0.25 M acetate
buffer (pH 4.75), and the glycogen digested into glucosyl
unit overnight at 37 °C. Glucose was measured using a
commercial glucose oxidase kit (Sigma-Aldrich).
Statistical analysis

Statistical analysis was performed using SPSS Statistics
software (version 21, IBM, IL, USA). Data was tested for
normality using Shapiro-Wilk W tests. Outliers of ±2
SD were removed. Analysis of Variance (ANOVA) tests
were employed to examine treatment effects on levels of
plasma glucose, total sphingolipids and protein expression. Multivariate ANOVA (MANOVA) tests were used
to examine treatment effects on levels of ceramide and
sphingolipid species. Post-hoc analysis was performed
using Bonferroni tests for multiple comparisons. Significance was accepted if p < 0.05.

Results
Fasting plasma glucose levels

An ANOVA revealed a significant effect of treatment on
fasting plasma glucose levels (F2,35 = 15.06, p < 0.0001), with
the clozapine group exhibiting significant hyperglycemia
compared to the controls (p < 0.0001); however, no significant differences in glucose levels were observed in the
olanzapine treatment group (p > 0.05 vs controls) (Fig. 1).
In order to investigate a potential mechanism underlying

a
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the clozapine-induced hyperglycaemia, we examined liver
glycogen levels and observed a decrease (− 39%) in
glycogen content in the clozapine group compared to the
controls (p < 0.05) (Fig. 1).
Sphingolipid levels
Ceramide levels

There was a significant effect of treatment on total ceramide concentration in the liver (F2,16 = 131.59, p < 0.
0001), with reduced levels following clozapine treatment
compared to the controls (p < 0.0001). In contrast, no
difference in ceramide concentration was observed in
the olanzapine group (p > 0.05 vs controls) (Fig. 2). Further examination of individual ceramide species identified a lower level of Cer 16:0, Cer 24:2 (p < 0.01), Cer 22:
0, Cer 23:0, Cer 24:0, Cer 24:1, Cer 25:0 (p < 0.0001) in
the clozapine group compared to the controls (Fig. 2).
There were no differences in the levels of Cer 18:0, Cer
19:0, Cer 20:0, Cer 22:1 in the clozapine group or in any
of the ceramide species in the olanzapine group compared to the controls (all p > 0.05) (Fig. 2). We also examined treatment effects in the skeletal (gastrocnemius)
muscle and found no significant effect of treatment on
total ceramide (F2,16 = 4.09, p < 0.05) or individual ceramide species in the skeletal muscle (p > 0.05) (Table 1).
Sphingomyelin levels

A significant treatment effect on total sphingomyelin
levels was identified (F2,16 = 90.43, p < 0.0001), with
lower levels in the clozapine group (p < 0.0001) and
higher total sphingomyelin levels in the olanzapine
group (p < 0.05) compared to the controls (Fig. 3). Analysis of sphingomyelin species revealed a significant decrease in the levels of SM 20:0, SM 21:0 (p < 0.05), SM
17:0, SM 25:1, SM 26:0, SM 26:1 (p < 0.01), SM 16:0, SM
22:0, SM 22:1, SM 23:0, SM 23:1, SM 24:0, SM 24:1, SM
24:2 and SM 25:0 (p < 0.0001) in the clozapine group
compared to the controls (Fig. 3). There was no treatment effect on the levels of SM 15:0, SM 16:1, SM 18:0,

b

Fig. 1 Glucose and Glycogen: (a) Fasting blood glucose levels (mmol/L) and (b) hepatic glycogen content (nmol/mg tissue) in female Sprague
Dawley rats following acute administration of olanzapine (1 mg/kg), clozapine (12 mg/kg) or vehicle (control). Data presented as mean ± SEM, (n
= 11–12/group). *p < 0.05 vs controls, ****p < 0.0001 vs controls
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a

b

c

Fig. 2 Hepatic Ceramide: Levels of (a) total ceramide, (b) lower abundance ceramide species and (c) higher abundance ceramide species (nmol/g
tissue wet weight) in the rat liver following acute administration of olanzapine (1 mg/kg), clozapine (12 mg/kg) or vehicle (control). Data
presented as mean ± SEM, (n = 6–7/group). **p < 0.01 vs controls, ****p < 0.0001 vs controls

SM 18:1, SM 19:0 or SM 20:1 (all p > 0.05) (Fig. 3). On the
other hand, olanzapine significantly increased levels of SM
22:0, SM 24:1 (p < 0.05) and SM 23:0 (p < 0.01), while the
remaining sphingomyelin species were unchanged by olanzapine treatment (Fig. 3). Similar to ceramide analysis, we
then investigated whether changes in sphingomyelin levels
were apparent in the skeletal (gastrocnemius) muscle and
found no treatment effects on total sphingomyelin (F2,16 =
4.09, p < 0.05) or sphingomyelin species (p > 0.05) (Table 1).
Protein expression of metabolic markers in the liver
Lipid metabolism

To investigate potential mechanisms underlying the altered sphingolipid concentrations in the liver we examined protein expression levels of CerS2 and ELOVL1.
There was a significant effect of treatment on the level of
CerS2 protein expression (F2,14 = 6.94, p < 0.01), with
higher expression in the clozapine group compared to the
controls (p < 0.05) and no change in the olanzapine group
(Fig. 4). There was a trend toward a significant treatment
effect in the levels of ELOVL1 expression (F2,9 = 3.36, p
= 0.08), with a + 37% increase in the clozapine group

compared to the controls (Fig. 4). In addition, there were
no significant differences in the level of total and phosphorylated ACC1 and FAS between the antipsychotic
treatment groups and the controls (all p > 0.05, Fig. 4).
ER stress markers

As ceramide synthesis occurs in the ER [47] and ER
stress has been associated with hyperglycemia [14], we
examined phosphorylation of IRE1 and eIF2α, two of the
main initiation factors of the unfolded protein response.
There were no significant treatment effects on IRE1 and
Elf2a phosphorylation (p > 0.05), although phosphorylation of eIF2α was 52.5% higher in the clozapine group
compared to the controls (Fig. 4).

Discussion
The pathogenesis of insulin resistance and DM is highly
complex and this complexity is compounded when diabetes occurs as a side-effect of antipsychotic drug treatment. This study aimed to capture changes that occur
within the first 1-h post-antipsychotic drug administration in an effort to understand the initial drug impacts
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Table 1 Ceramide and Sphingomyelin in Skeletal Muscle: Levels
of ceramide and sphingomyelin (nmol/g tissue wet weight) in
the rat skeletal muscle (gastrocnemius) following acute
administration of olanzapine (1 mg/kg), clozapine (12 mg/kg) or
vehicle (control). Data presented as mean ± SEM, (n = 6–7/
group)
Control

Olanzapine

Clozapine

Ceramide
Total

49.08

±

1.19

33.96

±

6.03

47.65

±

2.81

Cer 16:0

3.96

±

0.72

2.05

±

0.38

3.77

±

1.02

Cer 18:0

22.71

±

1.84

18.75

±

2.50

24.77

±

0.91

Cer 19:0

0.79

±

0.03

0.60

±

0.17

0.82

±

0.07

Cer 20:0

3.40

±

0.11

2.93

±

0.27

2.33

±

0.33

Cer 22:0

3.35

±

0.40

3.28

±

0.32

2.65

±

0.28

Cer 22:1

0.31

±

0.15

0.20

±

0.10

0.37

±

0.14

Cer 23:0

2.17

±

0.29

2.14

±

0.03

1.66

±

0.23

Cer 24:0

7.08

±

0.97

6.71

±

0.68

6.08

±

0.93

Cer 24:1

5.32

±

0.40

3.46

±

0.23

4.49

±

0.70

Cer 24:2

0.84

±

0.10

0.44

±

0.21

0.71

±

0.17

Cer 25:0

0.30

±

0.14

0.31

±

0.14

0.30

±

0.15

Sphingomyelin
Total

521.23

±

20.74

409.07

±

69.83

472.09

±

17.39

SM 16:0

59.07

±

12.48

51.95

±

9.07

64.12

±

8.68

SM 17:0

5.98

±

0.45

5.35

±

0.23

5.91

±

0.48

SM 18:0

241.68

±

10.63

213.19

±

20.40

253.40

±

9.12

SM 18:1

11.29

±

0.59

9.44

±

1.29

10.44

±

0.39

SM 19:1

4.78

±

0.18

4.57

±

0.22

4.78

±

0.18

SM 20:0

25.45

±

3.31

23.43

±

2.63

15.27

±

1.61

SM 22:0

37.96

±

5.27

43.44

±

6.70

23.39

±

2.75

SM 22:1

4.51

±

0.98

4.68

±

1.09

2.68

±

0.88

SM 23:0

14.60

±

1.48

18.36

±

2.68

10.25

±

1.09

SM 24:0

42.86

±

4.73

48.30

±

7.24

29.11

±

2.39

SM 24:1

66.81

±

8.28

49.84

±

2.33

45.62

±

4.91

SM 24:2

8.69

±

0.58

7.06

±

0.25

7.12

±

1.02

that could lead to the progression of metabolic sideeffects during chronic treatment. This study provides
the first evidence that acute clozapine administration
significantly disrupts sphingolipid levels in the liver, with
a robust reduction in hepatic ceramide and sphingomyelin content, and lipid species-specific effects, without
any respective changes in skeletal muscle. Interestingly,
the substantial clozapine-induced decrease in hepatic
sphingolipids was accompanied by increased CerS2 and
Elovl1 protein content, suggesting a potential compensatory reaction of the liver in an attempt to counterregulate the drastic non-physiological decrease in ceramide and sphingomyelin content.

This study coincides with the findings of McClay et al.,
[30] who observed significantly reduced levels of sphingolipid metabolites, specifically sphinganine, sphingosine
and phospocholine, in brain homogenates of male mice
administered haloperidol (a ‘typical’ first generation antipsychotic drug) for 28-days, suggesting an overall decrease
in sphingolipid content in the brain following haloperidol
administration. We provide the first evidence that antipsychotic drugs interfere with ceramide and sphingomyelin
levels in the liver, even after an acute dose; however, the
specific effects of acute antipsychotic administration on the
brain require further investigation. Given the high sphingomyelin content in the myelin sheathing that surrounds
axons, McClay et al., [30] concluded that the haloperidolinduced depletion of sphingolipids was indicative of demyelination in the brain. Narayan et al., [21] investigated
post-mortem prefrontal cortex samples from schizophrenia
subjects who were treated with typical antipsychotic drugs
and grouped based on time from initial diagnosis (i.e. recent diagnosis: < 5 years, or chronic illness: > 5 years). They
reported alterations in 18 genes that encode proteins of the
sphingolipid metabolism pathway in the recent diagnosis
cohort but not the chronic disease cohort, with further
real-time PCR analysis identifying reduced expression of
enzymes that produce ceramide from both the de novo
and salvage synthesis pathways compared to the controls
[21]. The authors acknowledged that the inability to exclude the effects of the typical antipsychotic drugs was a
limitation of the study, but suggested that the lack of
changes in the chronic schizophrenia cohort may indicate
that antipsychotic drugs had reversed the sphingolipid dysfunction [21]. Our results suggest that clozapine might
have an acute effect on the healthy brain; however further
studies examining chronic treatment effects on the brain in
healthy compared to schizophrenia cohorts would provide
further insight. Interestingly, antipsychotic naïve first episode schizophrenia patients also exhibit altered peripheral
(skin) ceramide profiles, with a lower total ceramide
fraction, but an increase in the concentration of particular
ceramide species in the schizophrenia patient cohort
compared to the controls [48]. In addition, analysis of prefrontal cortical and hippocampal samples from Df(16)A+/−
mice, a model of 22q11.2 chromosome deletion (a major
genetic risk factor of schizophrenia), identified alterations
in ceramide phosphoethanolamines and sphingomyelin
levels [49]. Overall, our findings combined with the literature demonstrate alterations in central and peripheral
sphingolipids in first episode and recently diagnosed schizophrenia, preclinical schizophrenia modelling, and as a result
of acute antipsychotic drug treatment (also see [29]).
In the present study, we examined the liver and skeletal muscle due to their role in metabolism and glucose
homeostasis. Clozapine decreased ceramide and
sphingomyelin levels in the liver, while olanzapine
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Fig. 3 Hepatic Sphingomyelin: Levels of (a) total sphingomyelin, (b) lower abundance sphingomyelin species and (c) higher abundance
sphingomyelin species (nmol/g tissue wet weight) in the rat liver following acute administration of olanzapine (1 mg/kg), clozapine (12 mg/kg) or
vehicle (control). Data presented as mean ± SEM, (n = 6–7/group). *p < 0.05 vs controls, **p < 0.01 vs controls, ****p < 0.0001 vs controls

increased hepatic sphingomyelin and neither drugs
altered lipids in the muscle. Further investigation is
required in order to understand why clozapine, and to a
lesser extent olanzapine, targeted sphingolipid metabolism in the liver and not the skeletal muscle. It is possible
that effects were observed after 1-h in the liver as both
antipsychotics are primarily metabolised by cytochrome
P450 enzymes in the liver [50]. These results could also
suggest that clozapine acutely increases hepatic glucose
output related to altered sphingolipid metabolism in the
liver, whereas sphingolipid changes in the muscle could
be related more closely to peripheral insulin resistance
associated with chronic treatment conditions. Indeed,
hyperglycemia and significantly lowered hepatic glycogen content was evident in the acute clozapine treatment group compared to the controls, suggesting an
effect of clozapine on hepatic glucose output. Increased
hepatic glucose output induced by clozapine is consistent with previous reports [8–10]. The lack of hyperglycemia in the olanzapine group was contrary to our
previous findings that olanzapine increased fasting glucose levels after 14-days of treatment [39, 51], and other
studies of acute treatment in rats [8], likely due to differences in treatment period and dose (7.5 mg and 15 mg

olanzapine in Boyda et al., [8]). Nevertheless, it enabled
examination of hepatic sphingolipid levels following
acute administration of two antipsychotic drugs with
similar characteristics, in the absence and presence of
hyperglycemia. Olanzapine is a thienobenzodiazepine
derivative with structural and pharmacodynamic similarities to clozapine [52]. They have similar receptor binding profiles in the brain and both have the highest
liability for causing metabolic side-effects [2, 52, 53].
However, there are clinical distinctions between these
two antipsychotics as clozapine can be an effective therapy for treatment resistant schizophrenia [54], suggesting some difference in mechanism of action compared
to olanzapine. An important finding of the present study
is that the drugs cause different effects during the acute
treatment phase. The lack of hyperglycemia in the olanzapine group could be related to the general lack in
changes in hepatic sphingolipid metabolism in this
group compared to the clozapine group. Future studies
that examine treatment effects over time may be beneficial in order to determine whether olanzapine and clozapine have the same effects on the parameters examined
in the present study after a longer period of time. On
the other hand, numerous reports examining the
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Fig. 4 Western Blot: Examples of Western blot protein expression are shown in (a). Levels of (b) ceramide synthase 2 (CerS2), (c) elongation of
very long chain fatty acids 1 (ELOVL1), (d) inositol-requiring enzyme (IRE1) and (e) eukaryotic initiation factor 2 (eIF2α), (f) acetyl CoA carboxylase
(ACC1) and (g) fatty acid synthase (FAS) protein expression (% of control) in the rat liver following acute administration of olanzapine (1 mg/kg),
clozapine (12 mg/kg) or vehicle (control). Data presented as mean ± SEM, (n = 4–6/group). *p < 0.05 vs controls

mechanisms and prevention of antipsychotic-induced
metabolic side-effects have focussed on long-term treatment effects [2, 39, 51, 55–60], but this study revealed
that antipsychotics can cause alterations to metabolic
parameters even after 1 h. By identifying the initial disruptions caused by olanzapine and clozapine in the
acute treatment phase, we can enhance understanding of
the mechanisms underlying metabolic side-effects that
manifest during long term treatment.
In order to understand a potential mechanism by
which clozapine and olanzapine alter longer chain
sphingolipid levels, we examined protein expression of
CerS2 and ELOVL1. CerS2 yields C22–24 ceramide species [22] and regulates ELOVL1 that synthesises long
(C18-C26) fatty acid chains [25]. CerS2 and ELOVL1
knockdown reduces endogenous C24 sphingolipid levels
in-vitro [25, 47]. Indeed, we observed reduced ceramide
and sphingomyelin 24:0, 24:1 and 24:2 levels in the clozapine treatment group, but a paradoxical increase in
both CerS2 and ELOVL1 protein expression levels,
which may be a compensatory mechanism attempting to
restore lipid homeostasis. The dramatic reduction in

ceramide levels by clozapine, an obesogenic/diabetogenic
antipsychotic drug, contrasts with the evidence that
increased ceramide levels are a cause of diet-induced nonalcoholic fatty liver disease, while reduced hepatic
ceramide levels increases insulin sensitivity [18, 19, 27,
61, 62]. In addition, one study showed that hepatic
CerS2 haploinsufficiency increased susceptibility of
mice to diet-induced hepatic steatosis [63], while clozapine increased hepatic CerS2 protein expression in the
present study. These differences may be reconciled by the
fact that the present study utilised an acute treatment
paradigm. It is possible that the dramatic reduction in ceramide caused by clozapine is an initial disruption to
sphingolipid homeostasis that results in a compensatory
(inappropriate) upregulation of ceramide synthesis during
chronic treatment. The upregulated CerS2 and ELOVL1
enzyme expression supports this notion; however, further
investigation is required. On the other hand, olanzapine
increased sphingomyelin levels, which could be an early
indicator of hepatic lipid accumulation in line with previous reports that olanzapine promotes lipid accumulation
in adipocytes and the liver [5, 7, 13, 39].
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The present study has revealed early disruption of
sphingolipid metabolism preceding antipsychoticinduced body weight gain. One possible explanation for
the reduction in ceramide and sphingomyelin species in
the clozapine group is their conversion to other lipid
metabolites. For example, ceramide can be converted to
sphingosine or glucosylceramide. As mentioned, sphingosine is reduced in haloperidol-treated mouse brains [30]
whereas glucosylceramide levels are upregulated in the
retinas of hyperglycaemic diabetic rats [64], but enzymes
catalysing the conversion of ceramide to glucosylceramide
are unaltered in typical antipsychotic drug-treated schizophrenia brain tissue [21]. Overall, despite the complexity
of the pathways surrounding ceramide metabolism [20],
further investigations into the effects of antipsychotic
drugs on other components and regulators of the sphingolipid metabolism pathways are justified.
Hyperglycemia can induce ER stress, which is considered a major contributor to hepatic insulin resistance by
favouring de novo lipogenesis (leading to hepatic lipid
accumulation), and interfering in insulin signalling, in
part, through IRE1/c-Jun N-terminal kinase (JNK) pathway activation (leading to hepatic insulin resistance and
DM) [14, 65]. In addition, the ER is a site for ceramide
synthesis and fatty acid elongation [7, 22, 47]. Therefore,
we examined whether ER stress may have impacted
ceramide levels in the present study. While some
evidence shows that hepatic CerS2 overexpression
reduces ER stress [12] other data show that decreased
complex sphingolipids increases ER stress [26]. We did
not observe significant changes in IRE1 phosphorylation,
but did observe a 52.5% increase in the eIF2α phosphorylation, indicating a clozapine-induced activation of the
PERK-Elf2a ER stress pathway.

Conclusions
This study provides the first evidence that antipsychotic
drugs with a high risk of causing metabolic side-effects,
olanzapine and clozapine, disrupt sphingolipid homeostasis in the liver within one hour of administration.
Clozapine causes a robust reduction in hepatic ceramide
and sphingomyelin levels, coupled with a potentially
compensatory upregulation of ceramide synthesising
enzymes (CerS2 and ELOVL-1), in the presence of
hyperglycemia and evidence of hepatic ER stress. On the
other hand, olanzapine increased hepatic sphingomyelin
levels, which is consistent with its ability to increase
hepatic lipid accumulation. A limitation of this study
was that we examined female rodents, which confer a
greater sensitivity to metabolic side-effects than males
[33]. Therefore, examination in males is required. In
addition, the estrus stage of the individual rats could
impact glucose metabolism through effects of estrogen
and progesterone [66]; however, the small standard error
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of the mean in the glucose and glycogen data sets of the
present study suggest low within-group variability. In
addition, further time-dependent studies are required to
elucidate the causal mechanism underlying this
antipsychotic-induced lipid dysfunction in the acute
treatment period in order to prevent the possible consequences, such as hepatic insulin resistance, lipid accumulation and DM, observed in treated individuals
during chronic antipsychotic treatment.
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